Methods of treatment of HDAC inhibitor valproic acid in RSV infection
By regulating RSV infection with the HDAC inhibitor valproic acid (VPA), reducing viral load and inflammatory response, the shortcomings of the treatment of RSV infection in the prior art were solved, and effective inhibition of RSV and reduction of pulmonary inflammation were achieved.
Patent Information
- Application Number
- CN202411000386.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-08
AI Technical Summary
The existing treatments for RSV infection lack effective targeted treatments, especially in inhibiting viral replication and reducing airway inflammation, and the role of HDAC in regulating paramyxoviral infection has not been fully studied.
Use of the HDAC inhibitor valproic acid (VPA), to reduce RSV viral load through epigenetic regulation, modulates the response of immune cells and cytokines to infection, thereby alleviating viral infection. Specific methods include detecting the effect of VPA on HDAC1/2 and GIMAP7 expression in normal human lung epithelial cell lines, conducting cytotoxicity tests, RT-qPCR detecting the expression of RSV and HDAC1/2, indirect immunofluorescence detecting the fluorescent signal of RSV, and Validation of VPA's anti-RSV infection effect in animal models.
VPA can inhibit RSV infection to varying degrees, maintain the normal physiological structure of lung tissue, reduce the release of inflammatory factors, and significantly reduce RSV viral load and lung inflammation, demonstrating the practical value of anti-RSV infection.
Smart Images

Figure CN118903083A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biomedicine, and in particular to a method of treating RSV infection using valproic acid, an inhibitor of HDAC. Background Art
[0002] Human respiratory syncytial virus (RSV) is a negative-sense RNA virus belonging to the family Paramyxoviridae and is the leading cause of epidemic bronchiolitis and pneumonia in children. With no effective vaccine currently available, this ubiquitous viral infection is associated with 40-60% of bronchiolitis cases and 15-25% of pneumonia cases in hospitalized children. Worldwide, severe RSV infection in infants is associated with substantial morbidity, and previous findings suggest that RSV infection early in life increases the risk of asthma. Therefore, prevention of RSV disease is of great importance.
[0003] In addition to direct epithelial injury, RSV infection in infants and immunocompromised patients often causes severe airway inflammation, which involves the release of multiple proinflammatory mediators and the recruitment of inflammatory cells to the peribronchial and perivascular spaces, as well as increased mucus production; therefore, inhibition of viral replication and reduction of virus-induced airway inflammation are appropriate therapeutic targets for severe RSV infection.
[0004] Protein acetylation is an important epigenetic modification mode that plays a key role in host defense against viral infections. Histone deacetylases (HDACs) are enzymes that remove acetyl fragments from specific lysine residues on histones to regulate chromatin structure and gene expression. These enzymes also post-translationally modify many non-histone targets, including transcription factors, chaperones, and signaling molecules, leading to changes in protein stability, protein-protein interactions, and protein-DNA interactions to control various cellular functions. The traditional HDAC family consists of 11 members, which require Zn2+ as a cofactor for deacetylase activity and are divided into four categories based on their homology.
[0005] Small molecule inhibitors of HDACs, such as trichostatin A (TSA) and suberoylanilide hydroxamicacid (SAHA), have been investigated as potential anticancer drugs. In addition to their anticancer activity, pan-HDAC inhibitors also have potent anti-inflammatory properties, and their efficacy in treating septic shock, rheumatoid arthritis, multiple sclerosis, and asthma has been demonstrated. HDAC inhibitors have been found to have antiviral effects, such as TSA and SAHA, which reduce the replication of hepatitis C virus (HCV). However, to our knowledge, the role of HDAC proteins in regulating paramyxovirus infection, especially RSV infection, has not been reported. VPA is a widely used anti-epileptic drug that inhibits the activity of HDAC1 and induces the degradation of HDAC2.
[0006] We found that valproic acid (VPA) is an orally active HDAC inhibitor that can inhibit the activity of HDAC1 and induce the degradation of HDAC2. VPA has also been used as an HDAC inhibitor to treat epilepsy for many years. Infections with other respiratory viruses, including SARS-CoV-2 and RSV, usually cause extensive lung damage in infected people, and this lung damage can cause long-term lung abnormalities (such as pulmonary fibrosis) observed in some recovered patients. For this reason, the HDAC inhibitor valproic acid is proposed as a treatment for RSV infection. Summary of the invention
[0007] The purpose of the present invention is that VPA reduces RSV viral load through epigenetic regulation, regulates the response of immune cells and cytokines to infection, and thus alleviates viral infection.
[0008] To achieve the above object, the present invention provides the following technical solution: a method for treating RSV infection using valproic acid, an inhibitor of HDAC, comprising the following steps:
[0009] S1: Cell culture and RSV infection
[0010] Normal human lung epithelial cell lines Beas-2b, PC9, and Hela were cryopreserved and stored by the Department of Microbiology, School of Basic Medical Sciences, Central South University. RSV (Long strain / A2 type) was stored by the Department of Medical Microbiology of Central South University. Cells were cultured under sterile conditions and maintained in DMEM and 1640 medium containing 10% fetal bovine serum (incubator at 37°C, 5% CO). 2 )
[0011] S2: Western blot analysis of the effect of VPA on the expression of HDAC1 / 2 and GIMAP7
[0012] Beas-2b cells with good cell growth status were plated in six-well plates. After the cells adhered to the wall, different concentrations of small molecule compound valproic acid (0mM, 0.5mM, 1mM and 2mM) were added. After 24 hours of action, cell RNA and cell protein were extracted for further experiments.
[0013] S3: CCK8 detection of VPA toxicity to Beas-2b and PC9 cells
[0014] The cytotoxicity test was performed using Cell Counting Kit-8. Beas-2b was plated in a 96-well cell culture plate at a density of 2×10 3 cells, and different concentrations of VPA (0 mM, 1 mM, 2 mM, 5 mM, 10 mM, and 20 mM) were added;
[0015] S4: RT-qPCR detection of RSV, HDAC1 / 2 expression and RSV viral DNA load
[0016] A small molecule compound cell group and a DMSO control group were established. Total RNA was prepared from Hela Beas-2b cells and analyzed using SmartSpec TM Plus spectrophotometer for quantification, total RNA was extracted from lung tissue using Trizol reagent, each sample was reverse transcribed into cDNA using RR036A PrimeScript RT Master Mix, and amplified using 2×SYBRGreen qPCR Master Mix according to the instructions;
[0017] S5: Indirect immunofluorescence detection of RSV fluorescence signal
[0018] Beas-2b cells were fixed with 4% paraformaldehyde and permeabilized with 0.4% Triton-X100. Lung tissue sections were permeabilized in 95% ethanol and 0.1% triton-X100, blocked with normal goat serum for 20 minutes, and incubated overnight at 4°C with monoclonal antibody against RSV major surface glycoprotein G rabbit. On the second day, the sections were washed 3 times with PBST for 4 minutes each time, and diluted goat anti-rabbit IgG / CY3 secondary antibody was added dropwise, incubated at 37°C for 1 hour, and then washed 3 times with PBST for 4 minutes each time. DAPI was added dropwise and incubated in the dark for 5 minutes (counter-staining nuclei), and finally the sections were washed 5 times with PBST for 4 minutes each time, and then the sections were sealed and observed and photographed under a confocal laser scanning microscope.
[0019] S6: Animal Models
[0020] Eighteen female BALB / c mice aged 4-6 weeks were randomly divided into a healthy control group, an RSV infection group, and a valproic acid intervention group (400 mg / kg). Each group of animals was first acclimated to the environment for 5-7 days under standard conditions. After isoflurane anesthesia, the mice were intranasally inoculated with RSV 5×10 6 pfu (100 μl);
[0021] S7: HE staining
[0022] The lung tissue of each animal was fixed in 10% formaldehyde solution for 24 h, then embedded in paraffin, cut into 5 μm slices, stained with hematoxylin-eosin according to routine experimental procedures, and observed for tissue morphological changes under an optical microscope;
[0023] S8: Enzyme-linked immunosorbent assay (ELISA)
[0024] Mouse lung homogenates were collected and ELISA kits were used to measure the levels of IL-1β, IL-6, and TNF-α. Mouse lung homogenates were centrifuged at 1000 rpm for 10 min at 4°C;
[0025] S9: Statistical analysis
[0026] With the help of Excel, the original count data were integrated and analyzed. With the help of Image J, a series of original images were digitized and the quantitative data were displayed at the same time. With the help of GraphPad Prism8 software, the original count data and quantitative data were processed and analyzed. The t-test was used to test the normality of the quantitative data that conformed to the normal distribution, and the non-parametric test was used to test the normality of the quantitative data that did not conform to the normal distribution. The above analysis results were expressed as mean ± standard error (Mean ± SEM). When p < 0.05, there was a statistically significant difference.
[0027] Preferably, when the cell density in S1 reaches about 85%, different concentrations of compound VPA are added at 1×10 4 The cells were infected with about PFU of RSV, and the RSV viral load was detected after 24 hours.
[0028] Preferably, in S3, cells are treated according to the CCK-8 kit protocol, and the spectrophotometric absorbance value of each well at 450 nm is measured using TECAN F50.
[0029] Preferably, the S4 uses CFX96 Touch TM Deep well real-time fluorescence quantitative PCR detection system, using TB under thermal cycling conditions Ex Taq was used for quantitative PCR (qPCR).
[0030] Preferably, in S5, the sample is washed five times with PBST, each time for 4 minutes, and then stained with DAPI for 5 minutes, and the sample is observed and photographed under a confocal laser scanning microscope.
[0031] Preferably, in said S6, for the simulated infection (control group), mice are given an equal amount of sterile PBS, and the small molecule compound VPA is intragastrically administered 2 to 4 hours after RSV infection.
[0032] Preferably, the supernatant is collected in S8, and the OD value is measured at 450 nm using TECAN F50.
[0033] Preferably, Adobe Photoshop 2021 and GraphPad Prism 8 software are used in the S9 to carry out image processing and drawing.
[0034] Compared with the prior art, the present invention has the following beneficial effects:
[0035] The VPA of the present invention is an orally active HDAC inhibitor that can inhibit the activity of HDAC1 and induce the degradation of HDAC2. However, RSV reduces histone acetylation by enhancing the expression of HDAC1 / 2, thereby inhibiting the expression of the antiviral protein GIMAP7. The ability of VPA to inhibit RSV by inhibiting HDAC1 / 2 and increasing the expression of GIMAP7 was verified in the constructed in vivo and in vitro RSV infection model. The experimental results show that VPA can inhibit RSV infection to varying degrees and maintain the normal physiological structure of lung tissue, and has practical value in resisting RSV infection. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 is a graph showing the effect of expressing GIMAP7 on inflammation, natural immunity and RSV viral load of the present invention;
[0037] Figure 2 The epigenetic disappearance of GIMAPs in various immortalized lung cancer cell lines of the present invention (A) is a graph showing the disappearance of H3K27ac marks in the promoter region of GIMAPs;
[0038] Figure 3 It is a binding position map of HDAC1 and HDAC2 in the chromosome region where the GIMAPs gene is located;
[0039] Figure 4 is a diagram showing the effect of RSV infection on HDAC1 / 2 gene expression in cells;
[0040] Figure 5 is a graph evaluating the toxicity of VPA of the present invention against Beas-2b and PC9 cell lines;
[0041] Figure 6 It is a diagram showing the effect of VPA of the present invention on GIMAP7, HDAC1 / 2 and RSV virus in in vitro cells;
[0042] Figure 7 The VPA of the present invention can reduce RSV infection and the release of inflammatory factors in the lungs of mice caused by RSV infection;
[0043] Figure 8 This is a diagram showing that VPA of the present invention can improve the lung pathological state of mice infected with RSV;
[0044] Fig. 9 It is a graph showing that VPA of the present invention reduces the fluorescence signal of RSV in the lungs of mice. DETAILED DESCRIPTION
[0045] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0046] A method for treating RSV infection using valproic acid, an inhibitor of HDAC, comprises the following steps:
[0047] S1: Cell culture and RSV infection
[0048] Normal human lung epithelial cell lines Beas-2b, PC9, and Hela were cryopreserved and stored by the Department of Microbiology, School of Basic Medical Sciences, Central South University. RSV (Long strain / A2 type) was stored by the Department of Medical Microbiology of Central South University. Cells were cultured under sterile conditions and maintained in DMEM and 1640 medium containing 10% fetal bovine serum (incubator at 37°C, 5% CO). 2 ) and cultured until the cell density reached about 85%. Different concentrations of compound VPA were added at 1×10 4 The cells were infected with about PFU of RSV, and the viral load of RSV was detected after 24 hours;
[0049] S2: Western blot analysis of the effect of VPA on the expression of HDAC1 / 2 and GIMAP7
[0050] Beas-2b cells with good cell growth status were plated in six-well plates. After the cells adhered to the wall, different concentrations of small molecule compound VPA (0mM, 0.5mM, 1mM and 2mM) were added. After 24h of action, cell RNA and cell protein were extracted for further experiments.
[0051] S3: CCK8 detection of VPA toxicity to Beas-2b and PC9 cells
[0052] The cytotoxicity test was performed using Cell Counting Kit-8. Beas-2b was plated in a 96-well cell culture plate at a density of 2×10 3 cells, added different concentrations of VPA (0 mM, 1 mM, 2 mM, 5 mM, 10 mM and 20 mM), treated the cells according to the CCK-8 kit protocol, and measured the spectrophotometric absorbance of each well at 450 nm using TECAN F50;
[0053] S4: RT-qPCR detection of RSV, HDAC1 / 2 expression and RSV viral load
[0054] A small molecule compound cell group and a DMSO control group were established. Total RNA was prepared from Hela Beas-2b cells and analyzed using SmartSpec TM Plus spectrophotometer, total RNA was extracted from lung tissue using Trizol reagent, each sample was reverse transcribed into cDNA using RR036A PrimeScript RT Master Mix, and amplified using 2×SYBRGreen qPCR Master Mix according to the instructions. TM Deep well real-time fluorescence quantitative PCR detection system, using TB under thermal cycling conditions Ex Taq for quantitative PCR (qPCR);
[0055] S5: Indirect immunofluorescence detection of RSV fluorescence signal
[0056] Beas-2b cells were fixed with 4% paraformaldehyde and permeabilized with 0.4% Triton-X100. Lung tissue sections were permeabilized in 95% ethanol and 0.1% triton-X100, blocked with normal goat serum for 20 minutes, and incubated overnight at 4°C with monoclonal antibody against RSV major surface glycoprotein G rabbit. On the second day, the sections were washed 3 times with PBST for 4 minutes each time, and diluted goat anti-rabbit IgG / CY3 secondary antibody was added dropwise, incubated at 37°C for 1 hour, and then washed 3 times with PBST for 4 minutes each time. DAPI was added dropwise and incubated in the dark for 5 minutes (counter-staining nuclei), and finally the sections were washed 5 times with PBST for 4 minutes each time, and then the sections were sealed and observed and photographed under a confocal laser scanning microscope.
[0057] S6: Animal Models
[0058] Eighteen female BALB / c mice aged 4-6 weeks were randomly divided into a healthy control group, an RSV infection group, and a valproic acid intervention group (400 mg / kg). Each group of animals was first acclimated to the environment for 5-7 days under standard conditions. After isoflurane anesthesia, the mice were intranasally inoculated with RSV 5×106 pfu (100 μL), for mock infection (control group), mice were given an equal amount of sterile PBS and intragastrically administered with the small molecule compound VPA 2 to 4 h after RSV infection;
[0059] S7: HE staining
[0060] The lung tissue of each animal was fixed in 10% formaldehyde solution for 24 h, then embedded in paraffin, cut into 5 μm slices, stained with hematoxylin-eosin according to routine experimental procedures, and observed for tissue morphological changes under an optical microscope;
[0061] S8: Enzyme-linked immunosorbent assay (ELISA)
[0062] Mouse lung homogenates were collected and ELISA kits were used to determine the levels of IL-1β, IL-6, and TNF-α. Mouse lung homogenates were centrifuged at 1000 rpm for 10 min at 4°C, and the supernatants were collected. The OD values were measured at 450 nm using TECAN F50;
[0063] S9: Statistical analysis
[0064] With the help of Excel, the original count data were integrated and analyzed. With the help of Image J, a series of original pictures were digitized and the quantitative data were displayed at the same time. With the help of GraphPad Prism8 software, the original count data and quantitative data were processed and analyzed. The t-test was used to conduct a normal distribution test on the quantitative data that conformed to the normal distribution, and the non-parametric test was used to conduct a normal distribution test on the quantitative data that did not conform to the normal distribution. The above analysis results were expressed as mean ± standard error (Mean ± SEM). When p < 0.05, there was a statistically significant difference. AdobePhotoshop 2021 and GraphPad Prism 8 software were used to process images and draw pictures.
[0065] VPA promotes GIMAP7 to inhibit RSV replication and reduce inflammation
[0066] We then used RT-qPCR to analyze the effects of overexpression of GIMAP7 on inflammation, innate immunity, and RSV viral load. The results showed that overexpression of GIMAP7 in PC9 cells could significantly inhibit inflammation induced by RSV infection. However, GIMAP7 itself had no effect on the expression of IL6, CASP1, and IL1β (Fig. Figure 1 A), but GIMAP7 overexpression can significantly activate the expression of ISG15, a key innate immune gene (such as Figure 1 B), and overexpression of GIMAP7 can significantly reduce the amplification and replication of RSV virus in cells (such as Figure 1C).
[0067] Figure 1 Effects of GIMAP7 expression on inflammation, natural immunity and RSV viral load (n=5). (A) RT-qPCR detected the effect of overexpression of GIMAP7 on the transcriptional expression of inflammatory and pyroptotic genes IL6, CASP1 and IL1β, ns indicates no statistical difference, **p<0.01, ***p<0.001; (B) RT-qPCR detected the effect of overexpression of GIMAP7 on the mRNA expression of natural immune gene ISG15, ns indicates no statistical difference, **p<0.01, ***p<0.001; (C) Expression of GIMAP7 significantly reduced the replication of RSV virus in cells, **p<0.01, ***p<0.001.
[0068] Epigenetics is an important mechanism for regulating the expression of the GIMAP family
[0069] Through the analysis of Chip-seq data in ENCODE, we found that compared with normal lung tissue cells, the epigenetic mark of H3K27ac in the promoter region of GIMAPs family genes disappeared in various lung cancer cell lines (such as A549, IMR90 and PC9) (such as Figure 2 ), and the adjacent gene TMEM176B was consistent with GIMAPs, and its epigenetic mark H3K27ac also disappeared, but the epigenetic mark of the adjacent gene ZNF775 did not disappear. We then further analyzed the chromosomal binding positions of HDAC1 and HDAC2 in the region where the GIMAPs genes were located. The analysis results based on the transcription factor ChIP-seq data in ENCODE showed that HDAC1 and HDAC2 bound to a sequence of "AGATAACGAACAGACTTAAGTGGCCCCAGATTTCCAAGTATTTCTACTTCCTCTTTTTGACCA" between GIMAP5 and TMEM176B in K562 cells, that is, between 150787713 and 150787798 on chromosome 7 (such as Figure 3 ).
[0070] Figure 2 Epigenetic disappearance of GIMAPs in various immortalized lung cancer cell lines. (A) H3K27ac mark disappears in the promoter region of GIMAPs.
[0071] Figure 3 This is the binding position of HDAC1 and HDAC2 in the chromosomal region where the GIMAPs genes are located.
[0072] RSV infection can activate the expression of HDAC1 / 2
[0073] We speculated that RSV promoted RSV virus replication and the progression of clinical symptoms by upregulating the expression of HDAC1 / 2. To this end, we first detected the expression of HDAC1 / 2 after RSV infection. The results showed that RSV infection of Beas-2b and PC9 cells could activate the expression of HDAC1 / 2 mRNA (e.g. Figure 4 AB).
[0074] Figure 4 The effect of RSV infection on HDAC1 / 2 gene expression in cells (n=5). (A) RSV infection activated the expression of HDAC1 / 2 in Beas-2b cells, ns means no significance, **p<0.01, ****p<0.0001; (B) RSV infection activated the expression of HDAC1 / 2 in PC9 cells, ns means no significance, **p<0.01, ***p<0.001.
[0075] Evaluation of cytotoxic concentrations of valproic acid
[0076] We tested the cytotoxicity of valproic acid in Beas-2b and PC9 cells. Figure 4 As shown, it was confirmed that the safe concentration of VPA is less than 5mM (such as Figure 5 ).
[0077] Figure 5 Toxicity evaluation of VPA against Beas-2b and PC9 cell lines (n=5), ns indicates no significance, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001;
[0078] VPA activates GIMAP7 expression and inhibits RSV in vitro by inhibiting HDAC1 / 2
[0079] To explore the effect of VPA on the expression of GIMAP7 and HDAC1 / 2, cells were treated with VPA at different concentrations, and the expression of GIMAP7 gene and protein was determined by RT-qPCR and Western-blot (WB). The experimental results showed that VPA could promote the transcription of GIMAP7 mRNA at a safe concentration, and this promotion was more obvious with the increase of concentration. However, VPA had no effect on the mRNA level of HDAC1 / 2 (such as Figure 6 A), in cells infected with RSV (MOI = 1) for 24 h, the addition of VPA can significantly reduce the viral load of RSV, and the effect is dose-dependent at a safe concentration (e.g. Figure 6 B).
[0080] Figure 6The effects of VPA on GIMAP7, HDAC1 / 2 and RSV virus in vitro cells (n=5). (A) Valproic acid can significantly activate the transcription of GIMAP7 mRNA in vitro cells, but has no effect on the transcription of HDAC1 / 2, ns means no significance, *p<0.05; (B) Valproic acid can significantly inhibit RSV virus gene transcription in vitro cells, *p<0.05, **p<0.01, ***p<0.001.
[0081] Valproic acid inhibits RSV infection by inhibiting the expression of Hdac1 / 2 and activating Gimap7 in vivo
[0082] In order to further clarify that RSV virus inhibits the expression of GIMAP7 by activating the expression of HDAC1 / 2, and to verify that VPA inhibits RSV virus infection by inhibiting the expression of GIMAP7 activated by HDAC1 / 2, we constructed an RSV acute infection mouse model (7 days) and a RSV infection model intervened by VPA, and analyzed the inflammatory factors in the mouse lung homogenate and the fluorescence signals of RSV in the lung by HE staining and ELISA, and then evaluated the anti-RSV ability of VPA.
[0083] First, the RSV viral load (VL), Gimap7 and Hdac1 / 2 gene expression in the lungs of experimental animals were measured by RT-qPCR, and the following results were obtained: In the in vivo experiment, Gimap7 was reduced after RSV infection, which was consistent with the in vitro experiment. However, when VPA treatment was implemented, the VL of RSV virus was greatly inhibited (such as Figure 7 A), while the downregulation of Gimap7 was reversed (e.g. Figure 7 B), when Gimap7 is low expressed, RSV infection is stronger. Then ELISA was used to measure the inflammatory factors in the lung homogenate of the experimental animals. The results showed that the animals treated with VPA significantly downregulated the expression of the three inflammatory factors IL-1β, IL-6 and TNF-α compared with the animals infected with RSV (such as Figure 7 C).
[0084] Figure 7 VPA can reduce RSV infection and the release of inflammatory factors in the lungs of mice caused by RSV infection (n=5). (A) Valproic acid can reduce RSV viral load in vivo, **p<0.01, ***p<0.001; (B) VPA can rescue the down-regulation of Gimap7 expression caused by RSV infection in vivo, *p<0.05, **p<0.01; (C) In the RSV infection and VPA intervention mouse model, ELISA detected the expression of IL-1β, IL-6 and TNF-α in mouse lung homogenate, ****p<0.001.
[0085] HE staining of mouse lungs showed that lung damage and lung inflammation in VPA-treated animals were significantly less than those in the positive control group (see Figure 8 ), and continued to measure the RSV fluorescence signal in the animal's lung tissue. It was observed that the number of RSV fluorescence signals in the lungs of VPA-treated mice was significantly smaller than that of the positive control group ( Fig. 9 ).
[0086] From the above results, it can be seen that VPA also plays a certain role in resisting RSV infection in the body, weakening the inflammatory activity of animals caused by RSV infection and enabling the lungs to maintain normal physiological structure. It has the potential to become a candidate drug for the treatment of RSV.
[0087] Figure 8 VPA can improve the lung pathological state of mice after RSV infection (HE staining, 100×, 200×).
[0088] Fig. 9 VPA reduced the fluorescence signal of RSV in the lungs of mice.
[0089] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device.
[0090] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A method for treating RSV infection using valproic acid, an inhibitor of HDAC, characterized in that: The method comprises the following steps: S1: Cell culture and RSV infection Normal human lung epithelial cell lines Beas-2b, PC9, and Hela were cryopreserved and maintained by the Department of Microbiology, School of Basic Medical Sciences, Central South University. RSV (Long strain / A2 type) was stored by the Department of Medical Microbiology of Central South University. Cells were cultured under sterile conditions and in DMEM and 1640 medium containing 10% fetal bovine serum (37°C incubator, 5% CO2); S2: Western blot analysis of the effect of VPA on the expression of HDAC1 / 2 and GIMAP7 Beas-2b cells with good cell growth status were plated in six-well plates. After the cells adhered to the wall, different concentrations of small molecule compound valproic acid (0mM, 0.5mM, 1mM and 2mM) were added. After 24 hours of action, cell RNA and cell protein were extracted for further experiments. S3: CCK8 detection of VPA toxicity to Beas-2b and PC9 cells The cytotoxicity test was performed using Cell Counting Kit-8. Beas-2b was plated in a 96-well cell culture plate at a density of 2×10 3 cells, and different concentrations of valproic acid (0 mM, 1 mM, 2 mM, 5 mM, 10 mM, and 20 mM) were added; S4: RT-qPCR detection of RSV, HDAC1 / 2 expression and RSV viral load A small molecule compound cell group and a DMSO control group were established. Total RNA was prepared from Hela Beas-2b cells and analyzed using SmartSpec TM Plus spectrophotometer for quantification, total RNA was extracted from lung tissue using Trizol reagent, each sample was reverse transcribed into cDNA using RR036A PrimeScript RT Master Mix, and amplified using 2× SYBR Green qPCR Master Mix according to the instructions; S5: Indirect immunofluorescence detection of RSV fluorescence signal Beas-2b cells were fixed with 4% paraformaldehyde and permeabilized with 0.4% Triton-X100. Lung tissue sections were fixed in 95% ethanol and 0.1% triton-x100, blocked with normal goat serum for 20 minutes, and incubated overnight at 4°C with monoclonal rabbit antibody to RSV major surface glycoprotein G. On the second day, the sections were washed 3 times with PBST for 4 minutes each time, and diluted goat anti-rabbit IgG / CY3 secondary antibody was added dropwise, incubated at 37°C for 1 hour, and then washed 3 times with PBST for 4 minutes each time, and DAPI was added dropwise and incubated in the dark for 5 minutes (counter-staining nuclei), and finally the sections were washed 5 times with PBST for 4 minutes each time, and then the samples were observed and photographed under a confocal laser scanning microscope. S6: Animal Models Eighteen female BALB / c mice aged 4-6 weeks were randomly divided into a healthy control group, an RSV infection group, and a valproic acid intervention group (400 mg / kg). Each group of animals was first acclimated to the environment for 5-7 days under standard conditions. After isoflurane anesthesia, the mice were intranasally inoculated with RSV 5×10 6 pfu (100 μl); S7: HE staining The lung tissue of each animal was fixed in 10% formaldehyde solution for 24 h, then embedded in paraffin, cut into 5 μm slices, stained with hematoxylin-eosin according to routine experimental procedures, and observed for tissue morphological changes under an optical microscope; S8: Enzyme-linked immunosorbent assay (ELISA) Mouse lung homogenates were collected and ELISA kits were used to measure the levels of IL-1β, IL-6, and TNF-α. Mouse lung homogenates were centrifuged at 1000 rpm for 10 min at 4°C; S9: Statistical analysis With the help of Excel, the original count data were integrated and analyzed. With the help of Image J, a series of original images were digitized and the quantitative data were displayed at the same time. With the help of GraphPad Prism8 software, the original count data and quantitative data were processed and analyzed. The t-test was used to test the normality of the quantitative data that conformed to the normal distribution, and the non-parametric test was used to test the normality of the quantitative data that did not conform to the normal distribution. The above analysis results were expressed as mean ± standard error (Mean ± SEM). When p < 0.05, there was a statistically significant difference.
2. The method for treating RSV infection using valproic acid, an HDAC inhibitor, according to claim 1, characterized in that: When the cell density in S1 reached about 85%, different concentrations of the compound valproic acid were added at 1×10 4 The cells were infected with about PFU of RSV, and the RSV viral load was detected after 24 hours.
3. The method for treating RSV infection using valproic acid, an HDAC inhibitor, according to claim 1, characterized in that: In S3, cells were treated according to the CCK-8 kit protocol, and the spectrophotometric absorbance of each well at 450 nm was measured using TECAN F50.
4. The method for treating RSV infection using valproic acid, an HDAC inhibitor, according to claim 1, characterized in that: The S4 uses the CFX96 Touch TM Deep well real-time fluorescence quantitative PCR detection system, using TB under thermal cycling conditions Ex Taq was used for quantitative PCR (qPCR).
5. The method for treating RSV infection using valproic acid, an HDAC inhibitor, according to claim 1, characterized in that: The S5 was washed five times with PBST, each time for 4 minutes, and then stained with DAPI for 5 minutes, and the samples were observed under a confocal laser scanning microscope.
6. The method for treating RSV infection using valproic acid, an HDAC inhibitor, according to claim 1, characterized in that: In the above S6, for the mock infection (control group), mice were given an equal amount of sterile PBS and intragastrically administered with the small molecule compound valproic acid (VPA) 2 to 4 hours after RSV infection.
7. The method for treating RSV infection using valproic acid, an HDAC inhibitor, according to claim 1, characterized in that: The supernatant was collected in S8, and the OD value was measured at 450 nm using TECAN F50.
8. The method for treating RSV infection using valproic acid, an HDAC inhibitor, according to claim 1, characterized in that: Adobe Photoshop 2021 and GraphPad Prism 8 software are used in the S9 to carry out image processing and drawing.
